M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Spirituality/Religiosity in Patients and Caregivers

Completed

Conditions: Advanced Cancer
Solid Tumors

Interventions: Behavioral: Questionnaires

First Posted Date: 2008-03-12

Last Posted Date: 2023-03-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 193

Registration Number: NCT00634257

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lifestyle Intervention for Heart Failure

Not Applicable

Active, not recruiting

Conditions: Heart Failure

Interventions: Other: Usual Care
Behavioral: Exercise Training
Behavioral: Dietary Counseling

First Posted Date: 2008-03-12

Last Posted Date: 2025-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 85

Registration Number: NCT00633633

Locations: 🇺🇸
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Intraoperative Optical Imaging of Brain Function

Withdrawn

Conditions: Brain Tumor

Interventions: Procedure: Speckle-Contrast Imaging

First Posted Date: 2008-03-10

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00632437

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Retrospective Study of the Biomechanical Properties of Large Allografts

Terminated

Conditions: Bone Cancer

Interventions: Procedure: Tissue Sample

First Posted Date: 2008-03-10

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00632294

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Lenalidomide

First Posted Date: 2008-03-10

Last Posted Date: 2020-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT00632359

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Screening for Familial Colorectal Cancer (CRC) Patients

Completed

Conditions: Colorectal Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2008-03-10

Last Posted Date: 2020-06-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 269

Registration Number: NCT00632515

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Leuprolide
Drug: Goserelin
Drug: Sunitinib Malate
Drug: Casodex
Radiation: Radiation Therapy (RT)

First Posted Date: 2008-03-07

Last Posted Date: 2015-01-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00631527

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Analysis of Parametrial Lymph Nodes as Sentinel Nodes in Patients With Cervical Cancer

Not Applicable

Completed

Conditions: Cervical Cancer

Interventions: Procedure: Single Photon Emission Computed Tomography
Procedure: Intraoperative Lymphatic Mapping

First Posted Date: 2008-03-07

Last Posted Date: 2016-05-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00631241

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Cancer
Solid Tumors

Interventions: Drug: Sodium Stibogluconate
Drug: Interferon Alpha-2b

First Posted Date: 2008-03-05

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT00629200

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Phase 2

Completed

Conditions: Tumor Lysis Syndrome

Interventions: Drug: As Needed Rasburicase
Drug: Fixed Dose Rasburicase

First Posted Date: 2008-03-05

Last Posted Date: 2013-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 82

Registration Number: NCT00628628

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy